Participants who initiated long-acting cabotegravir-rilpivirine had a high rate of adherence and virologic suppression, with ...

The investigational oral pre-exposure prophylaxis (PrEP) agent MK-8527 showed a similar, well-tolerated safety profile to ...

WHO endorses biannual injectable Lenacapavir for HIV prevention. This long-acting PrEP offers hope for high-risk groups and ...

A BREAKTHROUGH HIV drug that only needs to be injected twice a year to offer near-total protection from the virus and ...

For more than two decades, the global community has united to fight the HIV pandemic, achieving remarkable progress. New HIV transmissions and AIDS-related deaths have dropped significantly, and ...

As borders tighten, Global South citizens say they are being locked out of high-level talks that impact them the most.

Experts have proposed new treatment modes for older people with HIV. The new treatment does not cause the health-threatening ...

A new injectable drug known as lenacapavir could change how millions of people across the world and Africa in particular access HIV protective drugs, which historically have hard to come by.

WHO recommends twice-yearly injectable lenacapavir for HIV prevention, expanding PrEP options for key populations.

Globally, an estimated 4,000 adolescent girls and young women become infected with HIV each week, with sub-Saharan Africa accounting for more than 60% of these new infections, according to the World ...

The House passed legislation on Thursday clawing back $9 billion in federal funding for global aid projects, which would ...

Stay with us for continuous coverage of unfolding stories from every corner of Africa. From breakthrough economic initiatives ...